Brainstorm cell therapeutics announces presentations on nurown® at 2024 annual neals meeting

New york , sept. 24, 2024 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of cellular therapies for neurodegenerative diseases, today announced the acceptance of two abstracts featuring nurown® (msc-ntf or debamestrocel) at the 2024 annual northeastern amyotrophic lateral sclerosis consortium (neals) meeting, to take place october 21 - 24, in-person in clearwater, florida and virtually.
BCLI Ratings Summary
BCLI Quant Ranking